What CJC-1295 Is

• CJC-1295 is a long-acting analog of growth hormone-releasing hormone (GHRH).
• It binds to GHRH receptors in the pituitary gland to promote endogenous GH secretion and downstream increases in IGF-1 (insulin-like growth factor-1).
• When formulated with a drug-affinity complex (DAC), CJC-1295 circulates longer, extending its biological effects.

How It Works

In healthy adults, CJC-1295 has been shown to:

• Increase mean plasma GH by 2- to 10-fold for up to ~6 days after a single dose.
• Raise IGF-1 levels by ~1.5- to 3-fold for 9–11 days.

These effects reflect enhanced pituitary function rather than simply replacing hormone from outside the body, which is why many clinicians view CJC-1295 as a more physiological approach.

Potential Benefits Reported

Human clinical data remains limited but suggests measurable hormonal effects.

Here’s what research and clinical reports associate with CJC-1295-mediated GH/IGF-1 increases:

• Improved body composition: lean mass tends to improve while fat mass declines in some users — though robust, long-term human data is lacking.
• Enhanced recovery and repair: GH and IGF-1 are involved in tissue repair and protein synthesis.
• Support of metabolic health: GH influences lipid metabolism and energy balance.

Importantly, these observations arise from hormonal effects and not FDA-approved clinical indications; CJC-1295 is not approved as a drug for GH deficiency or anti-aging.

Safety and Evidence Limitations

CJC-1295 has been studied in small clinical trials, but large, long-term human studies are lacking.

Here’s what we do know about safety:

• Early clinical trials reported dose-dependent increases in GH and IGF-1 without serious adverse effects in healthy adults at certain doses.
• Serious events have occurred in unrelated research contexts. One Phase II trial of a CJC-1295–based drug for lipodystrophy was discontinued after a participant’s death, though the exact relationship to the peptide was unclear and the study was halted as a precaution.
• Peer-reviewed guidance warns that CJC-1295 and similar peptide therapies lack strong evidence of safety or clinical efficacy and should not replace approved GH therapies.

CJC-1295 Paired With Ipamorelin: Synergy and Science

What Ipamorelin Is

Ipamorelin is a peptide that acts as a growth hormone secretagogue, binding to ghrelin receptors to trigger GH release from the pituitary.

Unlike earlier secretagogues, ipamorelin does not significantly elevate cortisol or prolactin.

Together, CJC-1295 and ipamorelin are often combined to target GH via two complementary mechanisms:

• CJC-1295 prolongs GH pulse duration through GRH receptor activation.
• Ipamorelin amplifies pulse strength through ghrelin receptor activation.

Why People Stack Them

Proponents believe this pairing may:

• Amplify overall GH output.
• Blend sustained release (CJC-1295) with sharp pulses (ipamorelin).
• Support enhanced lean mass, recovery, sleep quality, and metabolic effects beyond either peptide alone.

Scientific Support vs. Limitations

There is evidence each peptide influences GH dynamics:

• CJC-1295 clearly raises GH and IGF-1 levels in controlled human studies.
• Ipamorelin selectively induces GH release without cortisol spikes.

Practical Takeaways

• CJC-1295 stimulates natural GH release and has measurable effects on GH/IGF-1 biomarkers in humans.
• Ipamorelin triggers GH secretion via a separate pathway, offering a biologically plausible synergy.
• Clinical outcomes in humans (like improved muscle strength or aging reversal) have not been proved in large, peer-reviewed studies.
• Both peptides are not FDA-approved for anti-aging or performance enhancement and carry regulatory and safety uncertainties.

Before considering any peptide therapy, seek professional medical evaluation with appropriate hormone lab monitoring and risk/benefit discussion.

Availability

Bowery Clinic’s CJC-1295 + Ipamorelin programs are available through clinician evaluation with a defined monitoring plan and outcome tracking. Candidates are assessed individually, with care plans tailored to history, labs, and goals.

To learn more or request a clinical consult, patients can contact Bowery Clinic for an intake and physician review. Bowery Clinic provides peptide telehealth services to patients in Arizona, California, Florida, Georgia, Illinois, Maryland, Michigan, Nebraska, New York, Pennsylvania, Texas, Virginia, Washington.

Bowery Clinic works exclusively with licensed 503A compounding pharmacies to ensure every medication meets the highest safety, purity, and sterility standards. We do not use or endorse research-grade peptides in any form, as they are not manufactured for human use and lack the regulatory protections required for safe medical treatment.